NVCR has fallen based on a misunderstanding of their revenue numbers. The analyst are assigning them a 15X revenue multiple (recent ISI number) for an emerging small biotech company. If you doubt this look under the news section of iHUB for NVCR.
If you use that same 15 multiple after Sawston approval (revenue to equal roughly $500 million with UK specials) it would afford NWBO a share price over $6.
Market Data 
Markets 
AI
